SRR1381889
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.454
- KRAS_SIGNALING_DN+0.392
- OXIDATIVE_PHOSPHORYLATION+0.246
- SPERMATOGENESIS+0.227
- ESTROGEN_RESPONSE_LATE+0.186
- UV_RESPONSE_DN+0.158
- MYOGENESIS+0.147
- ESTROGEN_RESPONSE_EARLY+0.118
- XENOBIOTIC_METABOLISM+0.073
- FATTY_ACID_METABOLISM+0.058
Top 10 suppressed
- MYC_TARGETS_V2-0.486
- INTERFERON_ALPHA_RESPONSE-0.474
- UNFOLDED_PROTEIN_RESPONSE-0.460
- IL6_JAK_STAT3_SIGNALING-0.450
- TNFA_SIGNALING_VIA_NFKB-0.446
- INTERFERON_GAMMA_RESPONSE-0.437
- G2M_CHECKPOINT-0.419
- MYC_TARGETS_V1-0.414
- E2F_TARGETS-0.412
- MITOTIC_SPINDLE-0.397
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1341763 | GTEX | — | 0.966 |
| 2 | SRR1408368 | GTEX | — | 0.959 |
| 3 | SRR1470703 | GTEX | — | 0.956 |
| 4 | SRR1375571 | GTEX | — | 0.953 |
| 5 | SRR1318163 | GTEX | — | 0.948 |
| 6 | SRR1336158 | GTEX | — | 0.943 |
| 7 | SRR1480059 | GTEX | — | 0.943 |
| 8 | SRR1350456 | GTEX | — | 0.939 |
| 9 | SRR1416999 | GTEX | — | 0.937 |
| 10 | SRR1375976 | GTEX | — | 0.936 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.454 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.392 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.246 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.227 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.186 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.158 | Inavolisib | — uncovered |
| MYOGENESIS | 0.147 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.118 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.073 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.058 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.058 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.053 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.045 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.023 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.019 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.014 | Temsirolimus | — uncovered |